Archive | Information

Neoadjuvant Dabrafenib/Trametinib Leads to High pCR Rates in Bulky Resectable Melanoma, But Recurrences Are Common

Phase II results demonstrated that nearly half of patients with resectable stage IIIB/C BRAF V600-mutant melanoma achieved pathologic complete response (pCR) with neoadjuvant combination therapy consisting of dabrafenib (Tafinlar) and trametinib (Mekinist).

Read the full story

Posted in Melanoma In The News, Information

Herpes Virus-Immunotherapy Combo Improves Melanoma Treatment

Melanoma is known to be a very aggressive and deadly form of skin cancer. Treatment can be challenging due to the likelihood of metastasis and drug-resistance.

Read the full story

Posted in Melanoma In The News, Information

Adjuvant Therapy With Dabrafenib Plus Trametinib May Provide Benefit in Melanoma

Dabrafenib plus trametinib adjuvant therapy significantly lowered the risk of recurrence in patients with BRAF V600E or V600K –mutation positive stage III melanoma compared with placebo, according to a study published in The New England Journal of Medicine.

Read the full story

Posted in Melanoma In The News, Information

Vitiligo Repigmentation after Nivolumab Therapy Indicates Tumor Relapse

A recently published report documents the curious case of a patient who was treated with the recently introduced drug nivolumab for melanoma and developed vitiligo spots during the course of treatment.

Read the full story

Posted in Melanoma In The News, Information

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories